PD-1/PD-L1 blockade therapy does not demonstrate efficacy in almost 80% of patients with cervical cancer, suggesting that the potential mechanism of PD-1/PD-L1 in immunotherapy remains to be further clarified. This evidence concerns the gene CD274 and cervical carcinoma.